The performance forecast and valuation estimate that the company's EPS for 2011-2013 will be 0.42 yuan, 0.58 yuan, and 0.79 yuan respectively. According to the price-earnings ratio of 25-30 times in 2011, the recommended inquiry range is 10.25 yuan to 12.3 yuan.
【长江证券】仟源制药新股分析:专注于抗耐药性抗生素的民营药企
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.